comparemela.com

Latest Breaking News On - Tsx venture exchange xrtx - Page 1 : comparemela.com

XORTX Reprices Warrants Issued in Connection with Previous

CALGARY, Alberta, April 30, 2024 (GLOBE NEWSWIRE) XORTX Therapeutics Inc. (“XORTX” or the “Company”) (NASDAQ: XRTX | TSXV: XRTX | Frankfurt: ANU), a.

Nick rigopulosKim golodetzAllen davidoffVenture exchangeTherapeutics incPrivate placementForced conversion rightFree trading sharesRespiratory viralTsx venture exchange xrtxOrtx therapeutics inc

XORTX Announces New Clinical Advisory Board Member

CALGARY, Alberta, March 27, 2024 (GLOBE NEWSWIRE) XORTX Therapeutics Inc. (

United statesBoston university medical centerRichard johnsonPalladio biosciencesRonald perronePetter bjornstadAnjay rostogiFederico maeseKim golodetzRon perroneCharles edelsteinNick rigopulosAllen davidoffEuropean medicines agencyClinical data interchange standards consortiumNational institute of health

XORTX Files an Amended and Restated Prospectus Supplement

NOT FOR DISTRIBUTION TO UNITED STATES NEWS WIRE SERVICESOR FOR DISSEMINATION IN THE UNITED STATES CALGARY, Alberta, Feb. 01, 2024 (GLOBE NEWSWIRE) .

British columbiaUnited statesUnited kingdomNick rigopulosAllen davidoffTherapeutics incFee for the initial servicesCompany capital incVenture exchangeCommon share unitCommon share unitsUnited states securities actPlutus bridge capitalConsulting agreementInitial feeInitial services

XORTX Reminds Shareholders to Vote ahead of the Proxy

The proxy voting deadline for XORTX shareholders to vote their proxies is 10:00 a.m. (Calgary time) on Monday, June 26, 2023. XORTX’s board of directors.

United statesAllen davidoffTherapeutics incVenture exchangeLaurel hill advisory groupNorth americaTsx venture exchange xrtxOrtx therapeutics inc

XORTX Announces Type D Meeting with FDA to be held May 1,

● Type D Meeting Requested to Accelerate XRx-008 Clinical Program ● CALGARY, Alberta, March 14, 2023 (GLOBE NEWSWIRE) XORTX Therapeutics Inc..

Nick rigopulosAllen davidoffDavid melamedTherapeutics incEuropean medicines agencyDrug administrationVenture exchangeClinical programTyped meeting requestedPlacebo controlledRandomized withdrawal design studyNovel oxypurinol formulationProgressing stageSurrogate endpointsDrug approvalTsx venture exchange xrtx

vimarsana © 2020. All Rights Reserved.